



## PHA-767491

**Catalog No: tcsc1208** 

Available Sizes		
Size: 10mg		
Size: 50mg		
Specifications		
<b>CAS No:</b> 845714-00-3		
Formula: C <sub>12</sub> H <sub>11</sub> N <sub>3</sub> O		
<b>Pathway:</b> Cell Cycle/DNA Damage		
<b>Target:</b> CDK		
Purity / Grade: >98%		
<b>Solubility:</b> 10 mM in DMSO		
Alternative Names:		

## **Product Description**

**Observed Molecular Weight:** 

CAY10572

213.24

PHA-767491 is a dual Cdc7/Cdk9 inhibitor, with  $IC_{50}$ s of 10 nM and 34 nM, respectively.





IC50 & Target: IC50: 10 nM (Cdc7), 34 nM (Cdk9) $^{[1][4]}$ , 240 nM (Cdk2), 250 nM (Cdk1), 460 nM (Cdk5), 220 nM (GSK3- $\beta$ ) $^{[4]}$ 

In Vitro: PHA-767491 inhibits proliferation in both cell lines with an IC $_{50}$  of 0.64  $\mu$ M in HCC1954 cells and 1.3  $\mu$ M in Colo-205 cells. PHA-767491 is effective DDK inhibitors in vitro, with IC $_{50}$  values of 18.6 nM. PHA-767491 (2  $\mu$ M) completely abolishes Mcm2 phosphorylation by 24 hours in HCC1954 cells<sup>[1]</sup>. PHA-767491 in combination with 5-FU exhibits much stronger cytotoxicity and induces significant apoptosis manifested by remarkably increased caspase 3 activation and poly(ADP-Ribose) polymerase fragmentation in HCC cells. PHA-767491 directly counteracts the 5-FU-induced phosphorylation of Chk1 and decreases the expression of the anti-apoptotic protein myeloid leukemia cell  $1ine^{[2]}$ . PHA-767491 (0-10  $\mu$ M) decreases glioblastoma cell viability in a time- and dose-dependent fashion, with IC $_{50}$  of approximately 2.5  $\mu$ M for U87-MG and U251-MG cells. PHA-767491 hydrochloride induces apoptosis in glioblastoma cells, suppresses glioblastoma cell proliferation, cell migration and cell invasion<sup>[3]</sup>.

*In Vivo:* PHA-767491 decreases Chk1 phosphorylation and increases in situ cell apoptosis in tumor tissues sectioned from nude mice HCC xenografts<sup>[2]</sup>.

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!